Buprenorphine-naloxone is a combination medication of an opioid partial agonist and opioid antagonist that is proven to be effective in outpatient management of opioid use disorder (OUD). Tramadol is a centrally acting analgesic. This commonly used pain medication inhibits serotonin and noradrenaline reuptake by acting as a selective agonist on opioid µ receptors. Transition and tapering high-dose tramadol to buprenorphine-naloxone is not well described in the literature. We report a case of a patient who was taking 1,000-1,250 mg of tramadol daily upon presentation to the clinic. She was originally prescribed 150 mg daily with escalation in dose and frequency over a 10-year period. The patient was converted to bupren-orphine-naloxone and has been successful in treatment of OUD for 1 year.

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2023.0774DOI Listing

Publication Analysis

Top Keywords

high-dose tramadol
8
agonist opioid
8
tramadol conversion
4
conversion buprenorphine-naloxone
4
buprenorphine-naloxone buprenorphine-naloxone
4
buprenorphine-naloxone combination
4
combination medication
4
opioid
4
medication opioid
4
opioid partial
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!